Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK31858 for Airway Mucus Hypersecretion
NCT06820749Phase 2Enrolling by invitation
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HSK31858 in asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Dec 2024; status: enrolling by invitation.
02
Drugs
HSK31858
03
Conditions
asthmabronchiectasischronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06820749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820749.